The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech ...

Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results ...

Zealand Pharma A/S (ZLDPF) shares ended the last trading session 8% higher at $72.28. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Douglas Pharmaceuticals, New Zealand’s largest privately owned pharmaceutical company, announces the launch of Winlevi® ...

Zealand Pharma A/S advanced stock charts by Barron's. View ZLDPF historical stock data and compare to other stocks, and exchanges.

Copenhagen, Denmark Saturday, April 26, 2025, 18:00 Hrs [IST] ...

Danish biotechnology company Zealand Pharma said on Thursday it had enrolled the first patient in a mid-stage trial with its weight-loss drug candidate petrelintide in people with overweight or ...

Singh will lead the discovery and clinical translation of peptide medicines, investing in new technologies, including data and computational science.

Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery Utpal ...

Zealand Pharma (ZLDPF) announces the appointment of Utpal Singh as Chief Scientific Officer. Utpal will join the executive team to lead ...

Zealand Pharma hires Eli Lilly veteran Utpal Singh as CSO to advance peptide platform, following Roche obesity drug deal and ...

Company announcement - No. 9 / 2025 Zealand Pharma launches long-term incentive programs for Zealand Pharma's Board of Directors, Corporate Management and employees for 2025 Copenhagen, Denmark, April ...